◆最新臨床試験/悪性腫瘍(Latest Clinical Trials Registry/ Malignancy)◆

UMIN000020815 2016/03/15 治療・ケア/Treatment 医薬品/Medicine 手技/Maneuver

・開始前/Preinitiation

T3/T4aもしくはリンパ節転移を有する食道胃接合部腺癌に対する術前S-1 + Oxaliplatin併用療法の第Ⅱ相臨床試験 exit_disclaimer.gif

A phase II study of systemic chemotherapy with S-1 plus oxaliplatin followed by surgery in T3/T4a and/or lymph node-positive advanced adenocarcinoma of the esophagogastric junction exit_disclaimer.gif

・【classification/分類項目】 食道胃接合部腺癌 adenocarcinoma of the esophagogastric junction

・【classification/分類項目】 公益財団法人がん研究会有明病院消化器化学療法科 Cancer Institute Hospital, Gastroenterological Chemotherapy Department

◆参考資料・関連情報 (reference materials & related information)◆

 

Adjuvant treatment for esophagogastric junction cancer (PubMed/Nihon Geka Gakkai Zasshi. 2015 Jan)

A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.(PubMed/Cancer Chemother Pharmacol. 2013 Oct)

 

◆【Basic Info】 JapicCTI-132158 2015/07/22 医薬品/Medicine

・参加者募集終了-試験継続中 ongoing, but not recruiting

HER2陽性の転移性胃食道接合部/胃癌患者を対象とした,トラスツズマブ及び化学療法との併用におけるペルツズマブの有効性及び安全性を検討する二重盲検,プラセボ対照,ランダム化,多施設共同第III 相試験 exit_disclaimer.gif

A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE METASTATIC GASTROESOPHAGEAL JUNCTION OR GASTRIC CANCER exit_disclaimer.gif

・【classification】 HER2陽性の転移性胃食道接合部又は【classification】 胃癌 HER2-positive metastatic gastroesophageal junction or gastric cancer

・【classification】 中外製薬 Chugai Pharmaceutical

・【classification】 Antibody preparation/ 抗体医薬品

・試験薬剤名:ペルツズマブ(Pertuzumab:商品名パージェタ) 抗HER2ヒト化抗体